KATELYNN DOUGHERTY SOPER: Open Payments
NPI 1083387369 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$558 in 10 payments from 5 companies in 2025. Trend: 2023 $211 · 2024 $772 · 2025 $558
Long term medical supply or device loan: $399Food & beverage: $159
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 4 | $399 |
| GlaxoSmithKline, LLC. | 3 | $72 |
| Ethicon US, LLC | 1 | $33 |
| AstraZeneca Pharmaceuticals LP | 1 | $29 |
| TerSera Therapeutics LLC | 1 | $25 |
Products named: KISQALI, JEMPERLI, BLENREP, Enseal X1, Zoladex.
Industry payments across MD — which companies pay providers there.
